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Preparation of Folic Acid-Carbon Dots-Doxorubicin Nanoparticles as Targeting Tumor 
Theranostics 
by 
Samson N. Dada 
 
Carbon dots (CDs) have attracted much attention as an excellent gene/drug delivery and 
biological imaging agent for early cancer theranostics. In this study, we prepared two series of 
nanoparticles (NPs), which are composed of (CDs) with a targeting agent, folic acid (FA), and a 
chemotherapeutic agent Doxorubicin (Dox). All the NPs and their intermediates were 
characterized using ultraviolet-visible spectroscopy (UV-vis), fluorescence spectroscopy, and 
Fourier transform-infrared spectroscopy (FT-IR). The drug loading capacity (DLC) and drug 
loading efficiency (DLE) of two series of FA-CDs-Dox were assessed using UV-vis absorption 
spectroscopy at the wavelength of 485 nm. Both showed good DLE and DLC results when 
compared to literature data. In addition, the cumulative release property of Dox from the FA-
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CHAPTER 1. INTRODUCTION 
 
Cancer is a leading global health concern. It is estimated that about 8.8 million people die 
of cancer each year, which equates to one out of every six death worldwide, this number far 
exceeds the total number of deaths from tuberculosis, malaria and HIV/AIDS combined.1 Our 
research target is to synthesize water-soluble, bio-absorbable nanoparticles (NPs) that will improve 
both diagnostic and therapeutic efficacy for cancer. Such theranostic NPs are composed of carbon 
dots (CDs) conjugated with a targeting agent, folic acid (FA), and an anticancer drug Doxorubicin 
(Dox).  
Statement of Problems 
At the time of this writing, reports from the World Health Organization (WHO) show that 
cancer prevalence has risen to 18.1 million new cases with one in five men and one out of six 
women globally estimated to develop cancer during their lifetime.2 It is however surprising that 
despite the cancer management treatment techniques such as, radiotherapy, chemotherapy, and 
hormone therapy available, the overall survival rate from cancer has not improved substantially 
over the past three decades.3,4 
Similar to many other deadly diseases, studies have shown that the best way to survive 
cancer is early detection – a stage of cancer characterized by low cellular heterogeneity and 
metastasis.5 Oftentimes, detecting early-stage cancer is an onerous task, because during this 
phase, there are low concentrations of cancerous cells and biomarkers present at the tumor site 
and in the bodily fluids.5, 6 Also, since most cancers are detected at the advanced stage, it has 
been difficult to describe the properties of early-stage tumors, which can be different from 
advanced-stage cancers. As more cancer cells presented in the late stage, there are more 
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significant changes in the epigenome, genome, proteome, and transcriptome. These challenges 
and much more can be solved using nanotechnology driven diagnostics as part of the 
nanomedicine field.5 For its part, this field provide novel strategies and innovations for early 
diagnosis and treatment of cancer. It offers competences to perform medical and diagnostics 
applications unattainable by other strategies.  
One challenge to improve cancer treatment outcome lies in personalized therapy that 
requires real-time feedback on the pharmacokinetics, target site localization, and the healthy 
organ accumulation of cancer drugs.7 Compared to other NPs, CDs have recently generated a 
great deal of attention due to their environmental safety, low-cost, and simple synthesis, 
functionalization and their potential application as a drug delivery vehicle. To facilitate their 
clinical transition, however, functionalized CDs require more exploration with regards to scale-
up of their biogenic synthesis. Also, since the majority of anticancer drugs are hydrophobic, they 
can be loaded into the hydrophilic NPs via physical adsorption. But such a method is not very 
reproducible due to the variance of the amount of the loaded drugs each time. This study will 
focus on the use of a novel strategy to overcome this limitation by covalently attaching 
anticancer drugs to FA-CDs complex. As a unique nanodevice, this NPs conjugate has multiple 
clinical applications for personalized diagnostics and therapeutic cancer treatment. 
Cancer Treatment 
There are various kinds of cancer treatment based on the type and stage of cancer. Some 
patients will receive only one type of treatment, while others might require a combination of 
more than one treatment type, such as surgery with chemotherapy or radiation therapy. Some 




Of the different types of cancer treatment earlier mentioned, chemotherapy is one of the 
prevailing treatment techniques used.8 It involves using drugs to attack and kill cancerous 
tumors. The chemicals work by stopping and abating the spread of malignant neoplasm. Usually, 
the drug contains chemicals that damage the DNA or RNA of a cancer cell by interfering with 
the process of their cell mitosis and meiosis. A regimen, which is a combination of two or three 
drugs are usually administered to the patients through oral means, via an injection, intravenously, 
intrathecal, and sometimes topically as determined by the oncologist.  The regimen usually can 
be administered during the early stages of cancer to lower the chances of the cancer relapsing or 
at an advanced stage to shrink tumor cells and alleviate symptoms.9 Unfortunately, most cancer 
drugs are indiscriminate and non-specific, as they kill both cancerous and healthy cells, which 
often leads consequential side-effects.8–10  Anemia, diarrhea, and hair loss are common adverse 
effects experienced when healthy red blood cells, mucous membranes, and hair follicles are 
affected by chemotherapeutic drugs.15  According to the National Cancer Institute, there are over 
sixty-eight drugs widely used in breast cancer treatment as approved by the Food and Drug 
Administration (FDA).6  
There are different classifications of anticancer drugs. Figure 1 shows the various kinds 
of classification of anticancer drugs. The typical chemotherapy drugs are alkylators, antibiotics, 
antimetabolites, topoisomerases inhibitors, and mitosis inhibitors. Drugs that act on cells are 
called cytotoxic drugs; an example of these are alkylating agents such as Cisplatin, Carboplatin 
and Oxaliplatin all of three which have a platinum coordination. Drugs such as Doxorubicin and 
Dactinomycin are antibiotics and are frequently used in treatment of acute myelogenous and 




Figure 1. Common classification of anticancer drugs.12  
 
Cancer Early Detection 
Studies have proven that successful treatment of cancer depends on early diagnosis and 
detection. Two major factors that contribute to detecting early-stage cancer are screening and 
giving guidance to the public about the importance of early diagnosis.  For example, the public 
should be aware of early warning signs of cancer, such as irregular bleeding, lumps, and wounds 
that will not heal. They should be informed on what they should do if they found out they had 
cancer. Screening is also an effective technique for early cancer detection. It involves conducting 
various tests on healthy people that show no physical symptoms of the disease. For cervical and 
breast cancer, mammography and cytological screening are very effective and common methods 




Theranostic NPs for cancer 
Theranostics is a term used to describe the medicines that involve the targeted therapies 
for various diseases based on specific diagnostic tests.13 Nanotechnology offers many benefits to 
develop NPs that would have both therapeutic and imaging functions for early to late-stage 
cancer detection and treatment. Over the last decade, nanoparticles made of carbon-based 
materials continue to draw attention in theranostic studies due to their capability to act as a drug 
delivery vehicle. Simple prototypes are designed for cancer studies and research, where carbon 
NPs are conjugated to a specific anticancer drug that is active towards an overexpressed receptor 
for bioimaging and drug delivery functions.14 Since studies have shown that amorphous carbon 
NPs emit in the visible region on surface modification which may be utilized in vivo imaging 
applications.15  
Carbon based nanomaterials, such as buckminsterfullerene (e.g., C60), carbon nanotubes 
(CNTs), graphene, quantum dots (QDs), and nanodiamonds, have drawn a large interest as 
potential drug delivery vehicles and imaging materials due to their special luminescence 
properties. For examples, light sources in the UV, visible and infrared region, which ranges from 
200 – 1000 nm can be employed in carbon-based NPs light-activated drug delivery therapies. 
Studies have reported that photothermal therapy (PTT), which involves the special NPs 
converting the light energy into heat to attack tumor cells through a process called 
photoablation.16,17 The use of carbon based NPs to carry the anti-cancer drugs into cancerous cell 
nuclei by pH-controlled endocytosis has also been reported.10 Figure 2 below shows the 





Figure 2. Carbon-based nanomaterials (CBNs) and their diverse applications in theranostics.17 
 
Quantum Dots (QDs) 
Inorganic QDs have been widely studied as a bioimaging and optical sensing agent due to 
their high quantum yield, chemical stability, and excellent photoluminescence behaviors. Before 
the development of CDs, inorganic QDs were first discovered for disease diagnosis and 
screening. The QDs’ confocal, multiphoton, and electron microscopic imaging have resolutions 
better than 10 nm. They were synthesized from heavy metals such as cadmium, tellurium, and 
selenium. Their core and shell usually are composed of semiconductors from inorganic 
compounds, such as CdS/ZnS, CdSe/ZnS. 18–22 Due to their size advantage, they were initially 
used in cancer immunotherapy for tracking molecules.23  
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Consequently, application of QDs in genetic disease diagnosis and screening have been 
reported.24 QDs have been widely used in vivo studies of small animals such as mice because 
they have better stability and quantum yield compared to organic fluorophores that absorb in the 
IR region.23 For instance, as shown in Figure 3, the application of QDs in the imaging of 
embryonic stem cells used one single excitation wavelength. This study reveals that 
semiconductor QDs can be applied in both in vivo and in vitro cellular imaging. The applications 
of QDs as biological imaging agents and drug carriers are also widely investigated.25 
Unfortunately, even though QDs have luminescent properties that are sometimes twenty times 
brighter and hundred times more stable than most fluorescent materials, studies have shown QDs 
can bind to certain thiol groups in the mitochondria of a cell causing cell apoptosis, which has 
prevented their use in clinical applications.23,26,27 
 
Figure 3.  Embryonic stem cells labeled with six different QDs were subcutaneously injected on 
the back of the athymic nude mice right after labeling (image taken with a single excitation   




Carbon Dots (CDs) 
During the last ten years, CDs have garnered more interest due to their unique properties 
and are frequently reported as better substitutes to inorganic quantum dots (QDs). CDs are 
generally classified as a group of quasi-spherical carbon NPs with  sizes not more than 10 
nm.10,29,30 Studies have shown that CDs are primarily of interest in biological applications due to 
their unique properties such as fluorescence, extremely high biological compatibility, and 
superficial synthetic route.31–33 Different sample preparation methods have been reported for 
these “nanolanterns” since their discovery. Generally, those methods are classified into two 
strategies; the “bottom-up” approach and the “top-down” approach.  The top-down approach 
usually involves the breaking down of large carbon material under very harsh conditions. Some 
examples of this method includes oxidative acid treatment, arc-discharge, laser ablation, and 
electrochemical exfoliation.11, 29, 32–35 
While the bottom-up approach, on the other hand, involves synthesis from small carbon 
containing precursors and chemicals that contain functional groups such acids, amines, and 
hydroxyl groups. 31 Some example of the bottom-up technique include; microwave, ultrasonic, 
hydrothermal, and acid treatment.30 Table 1 summarized the methods mostly used in preparation 
of CDs. 
Table 1.  Strategies employed in CDs synthesis.28, 36 
 
Top Down Synthesis Bottom-up Synthesis 
Arc discharge Hydrothermal treatment 
Electrochemical exfoliation Ultrasonic 
Laser ablation Microwave 




Each synthetic method mentioned in Table 1 has its advantages and disadvantages, some 
of which are outlined in Table 2 shown below. For example, chemical ablation is very much 
accessible but is usually done under a very harsh condition, involving multiple steps leading to a 
poor control over sizes. In this study, two series of CDs were prepared using the hydrothermal 
method, which is by far the most favorable, and the most commonly used technique for CDs 
synthesis. The reason for this is that the technique is generally cost effective, eco-friendly, and 
non-toxic.31,39 
Table 2. Advantages and disadvantages of common synthetic methods of CDs.39 
 
Synthetic Methods Advantages Disadvantages 
Chemical ablation Most accessible, various 
sources 
Harsh conditions, drastic 
processes, multiple-steps, poor 
control over sizes 
Electrochemical carbonization Size and nanostructure 
are controllable, stable, 
one-step 
Few small molecule precursors 
Laser ablation Rapid, effective, surface 
states tunable 
Low QY, poor control over 
sizes, modification is needed 
Microwave irradiation Rapid, scalable, cost 
effective, eco-friendly 





Poor control over sizes 
 
Furthermore, the optical properties of CDs are highly related to the reaction method, 
starting reactants, size of the particle, structure, and surface state, and therefore, can be regulated. 
CDs are known to exhibit an excitation-dependent wavelength, which has made it useful in 
multi-color imaging applications.  It is essential to keep in mind that the optical behavior of CDs 
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fluctuate and are inconsistent for different starting material and synthetic methods used. The 
mechanism for this behavior is puzzling, and the reason is largely unknown. 
Nonetheless, since future perspective of CDs focuses on clinical applications, the 
cytotoxicity of CDs, as well as their compatibility with living organisms, are being investigated. 
So far, biological in vivo studies carried out in mice and zebra fish showed that CDs have no 
apparent lethal effects. It is why CDs are preferable materials in biological application and in 
vivo studies in comparison to inorganic QDs.40–42  
Applications of CDs 
CDs have been employed in a wide range of applications such as drug delivery,30,43,44 
biological imaging,45–48 light emitting devices,49 and photo-catalysts. 50–53 Several studies 
continue to explore the potential application of CDs. Figure 4 below shows some common 
applications of CDs.  
 




Biological Imaging Applications 
One of the most commonly used application of CDs is in target-specific imaging 
applications. CD imaging have been widely explored in biological imaging of different types of 
organism and prokaryotes, such as bacteria, eukaryotes, and fungi. Sheng-Tao Yang and his 
group were the first to report the practical application of CDs in in vivo studies in 2009.40 
Polyethylene glycol-functionalized CDs were injected subdermal and intravenously into a lab 
mice. It was observed, as in the case of the subdermal injection, that the area injected exhibited a 
substantially high fluorescence but faded away in 24 hours post-injection. However, when the 
intravenous injection was carried out, only the bladder region showed fluorescence, 3 hours after 
this, CDs were found in the urine. Further ex vivo studies showed the accumulation of CDs on 
the kidney but not on the liver. This study showed that CDs can be removed from the body when 
injected intravenously.55The conditions for using CDs for biological imaging and diagnostic 
studies are challenging. The parameters, such as cytotoxicity, cellular uptake, 
hemocompatibility, and quick excretion from the body, need to be examined.56  
Drug Delivery Systems 
Drug delivery is a technique used for systematic target delivery and control of curative 
agents. Studies have shown that the surface of CDs can be modified for gene transfer and drug 
delivery functions. For instance, Liu et al. used polyethyleneimine (PEI) modified CDs for gene 
transfer and bioimaging studies.57 The study proved that CDs had both transfer ability and 
excellent fluorescence property that helped provide useful data for studies on plasmid DNA 
physiological conditions. It was noted that during the transfer process, CDs maintained their 
unique excitation-dependent fluorescence. Also, CDs modified with polyethylene glycol (PEG) 
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have also been conjugated with Dox to improve the specificity of Dox for cancer cells.58,59 
Figure 5 below shows applications of CDs loaded with Dox for targeting specific cancer cells.  
 
Figure 5. Some examples of CDs application in drug delivery systems.14 
Sensing 
The unique properties and fluorescence behavior of CDs have made them  useful 
materials for detecting a wide range of analytes, cations, micro and macromolecules, cells, and 
bacteria.60 Over the past decade, studies started to focus on fluorescence (FL) based sensing, due 
to their unique properties such as outstanding sensitivity, relatively quick response time, and 
affordability. In the early 2000’s fluorescent sensory materials such as organic dyes, quantum 
dots, fluorescent proteins, etc. have been developed. Even though the practical use of some of 
these materials have been reported, they often have worrisome disadvantages that have caused 
limitation of use. The surface of CDs, on the other hand, has been used for detection of mercury 
cations and thiols as reported by Lu et al.61. This unique ability to modify the surface of CDs has 
made them superior to many other materials used as biosensors. For instance, CDs obtained from 
using glucose as a precursor exhibited a high affinity for boric acid due to the hydroxyl groups 




The primary goal of this study is to prepare novel CDs based nanoparticles as potential 
theranostic for cancer treatment. The designed NPs (Figure 4) consist of three main components 
CDs, the targeting agent folic acid (FA), and the antic-cancer drug Doxorubicin (Dox), as 
illustrated in Figure 6.  The  research designs are summarized as following; 
1. To synthesize two series of CDs using the hydrothermal bottom-up approach.  
a. To change the ratio of the starting materials, two kinds of CDs will be prepared 
with different functionalities on the surface.  
b. To characterize CDs using UV-vis spectroscopy, fluorescence spectroscopy, and 
infrared spectroscopy. 
2. To prepare FA-CDs by conjugation of CDs to FA using a non-cleavable peptide bond 
linker. 
a. To characterize FA-CDs using UV-vis spectroscopy, fluorescence spectroscopy, 
and infrared spectroscopy 
3.To load anticancer drug Dox onto FA-CDs, via a pH cleavable bond. 
b. To characterize FA-CDs-Dox properties using UV-vis spectroscopy, fluorescence 
spectroscopy, and infrared spectroscopy 
a. To analyze the drug load content (DLC) and drug load efficiency (DLE) properties of 
FA-CDs-Dox 






Figure 6. Structural design of  FA-CDs-Dox cancer theranostics.  
 
Research Plan 
Two series of CDs will be first prepared using the hydrothermal technique by heating 
different ratio of citric acid, and ethylenediamine at 250 ⁰C.63 The precursors were strategically 
chosen as they can provide the –COOH, –NH2 and –OH functional groups for further 
modification. In order to improve the target specificity to the tumor cells, the CDs are 
permanently linked to FA via an amide bond. Furthermore, the FA-CDs NPs are used to 
facilitate the delivery of the anticancer drugs Dox through a pH-cleavable linker (electrostatic 
attraction).  
Folic Acid (FA) 
Folic acid is a water-soluble, low molecular weight vitamin that plays an essential role in 
cell survival and has high affinity to the folate receptors (FR). Three isoforms of the FR have 
been identified (FRα, FRβ, and FRγ), the α type is the most common subtype of FA transport. 
Different kinds of tumors, such breast, ovarian, pancreatic, lung, head and neck, prostate, ovarian 
cancers, and mesothelioma, overexpress of this FR.64,65  Generally, FR are 
glycosylphosphatidylinositol anchored cell receptors that are highly expressed in various types of 
cancer.  Interestingly, this type of cell receptor is not present in healthy cells.66 Several studies 
have reported the use of FA (as shown in Figure 7) in cancer studies.67–72 This is because FA can 
be easily conjugated to theranostic agents for targeted deliveries, also, its high affinity to the 
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folate receptor is sustained even after conjugation to the diagnostic and therapeutic agent (Kd  = 
10-10 M).73,74 Furthermore, studies have proven that FA consumption does not increase the risk of 
getting any form of cancer.75 Several drugs, ligands, and curative agents have linked to FA for 
tumor selective drug delivery. Some examples are protein toxins, chemotherapeutic drugs, 
oligonucleotides, radio-imaging agents, gene therapy vectors, and magnetic resonance imaging 
(MRI) contrast agents.73   
 
 
Figure 7. The chemical structure of folic acid  
Dox 
In the early 1950s, there was incessant search for anticancer compounds from soil-based 
bacteria such as the Streptomyces spp. Not too long after that, a new strain of the bacteria was 
isolated that produced an antibiotic that showed potency against mouse tumors. The new 
compound, which was named daunoribicin. However, it has serious side effect, such as cardiac 
toxicity. And then, scientists made genetic modification to the bacterium form Adriamycin. The 
Dox (Figure 8) was finally made to mitigate some series side effect.76 Dox is a potent, low-cost 
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chemotherapeutic drug, which belongs to the class of anthracyclines. Even though the full 
mechanism of action of Dox is not fully understood, Dox are known to interfere with the process 
of cell replication and transcription by DNA double-helix intercalation, mitochondrial 
dysfunction, and sometimes by oxidative stress by production of a reactive oxygen species 
(ROS).10,11,77,78  
 
Figure 8.  The chemical structure of Doxorubicin • Hydrochloride  
Unfortunately, similar to most other traditional anticancer drugs, Dox is indiscriminate 
and is also non-specific, which means that it attacks both cancerous and healthy cells. Some side 
effects, such as cardiomyopathy, have also been reported.79 The adverse effects and the non-
specific distribution of traditional chemotherapeutic drugs is one of the greatest challenges 
troubling cancer chemtherapy.8 Dox which is an amphipathic base has a pKa value around 8.3 
and in an environment of a pH of 7.4, it exists as a cation due to protonation of its amino 
functional group.80 This phenomenon has its advantage because Dox can be potentially loaded on 
the negatively charged carbon nanoparticles via electrostatic interaction and π-π stacking.14,30,81 
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This unique interaction has many times been utilized to deliver Dox to cancerous cell nucleus via 
a pH-controlled release system. Another mode of delivery of Dox that has been reported is via 
the formation of an amide bond or a Schiff base, and this is formed by reacting the amino group 
of Dox with the carboxylic acid functional group of the carbon NPs.82,83  
Fundamental Spectroscopic Techniques 
To study the photoluminescence of CDs and its based NPs, it is important to understand 
the theories behind optical spectroscopies such as absorption, fluorescence, and infrared 
spectroscopy. Figure 9 below shows different types of technique and their corresponding 
wavelength region.
 
Figure 9.  Wavelength Regions, Spectroscopic Methods, and Associated Transitions.84 
Absorption Spectroscopy 
When a sample is continuously exposed to a radiation, some portion of this radiation may 
be absorbed by the sample, which can be observed on an absorption spectrum.84,85 The Jablonski 
diagram, as shown in Figure 8, may be used to represent the discrete and quantized electronic 
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energy of different molecules. Before being exposed to a radiation, electrons mostly remain at 
the lowest occupied energy level otherwise known as the ground state. However, when electrons 
absorb light energy they move to a higher energy, or excited state.  
The photon absorbed by the sample is wavelength-dependent and is proportional to the 
absorbing sample concentration. In practice, the analyte to be studied is placed in a cuvette such 
that radiation can be allowed to pass through it, the amount of radiation passing through the 
sample solution is then compared to a reference solution. Molecules on absorption of energy 
photons typically moves to the lowest unoccupied molecular orbital (LUMO) from a highest 
occupied molecular orbital (HOMO), It is possible for a compound to exhibit more than one 
electronic transition as shown in Figure 10. 
 






UV-vis absorption spectroscopy typically ranges from 200 to 1000 nm.  Among them, the 
UV range is within 200 – 350 nm and the visible range is from 350 – 700 nm 84.  UV-vis 
absorption spectroscopy is a typical technique to characterize CDs.  Different absorption range 
has been reported for CDs depending on the starting material and the preparation methods. As 
Zhu et al. reported, two major peaks for the CDs are at 240 and 344 nm from four samples of 
CDs prepared using the same technique but at different temperatures. Fig. 11 shows the 
combined UV-vis absorption spectra of these four CDs samples. It is noted that as the 
temperature increases, the absorption peak at 344 nm (surface/molecule section) decreases while 
the peak at 240 nm (carbonic core section) increases.63 This temperature dependent behavior of 
CDs is frequently reported. The carbogenic core of CDs is known to increase on increase in 
temperature. To understand the emission behavior of CDs, the fluorescence spectroscopy is often 





Figure 11. The UV/Vis absorption of CD 1-4.63 
  
 Fluorescence Spectroscopy (FL) 
Another spectroscopic technique to characterize CDs based NPs is fluorescence 
spectroscopy. In fluorescence spectroscopy, the signal detected is from the radiation emitted 
from the analyte as it returns to the ground state after excitation. While in phosphorescence 
emission takes place at the triplet excited states, also more generally, phosphorescence is when 
the spin of the ground and excited states is different. In both cases, the analyte will first exhibit 
excitation as a result of absorption of energy radiation in the ultraviolet range before emission.87 
The typical fluorescence spectrum of CDs is dependent on the mode of preparation and the 
starting material used. In general, CDs exhibit an excitation dependent fluorescence behavior. 
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The experiments conducted by Zhu et al. show that CDs have an emission maximum wavelength 
at 443 nm, which explains why it appears blue when viewed under the UV lamp (Figure 12).31 
 
Figure 12. UV/Vis absorption (_____), PL excitation (------), and emission (--•--•) spectra of CDs 
in aqueous solutions. Insets show photographs of CDs in aqueous solution under visible (left) 
and UV (right) light. b) Excitation-dependent PL of CDs.31 
 
Infrared Spectroscopy 
The last optical spectroscopic technique we used to characterize the CDs based NPs is 
Fourier transform infrared spectroscopy (FTIR). Primarily these were used to identify the types 
of functional groups and bonds present in the samples. The types of bonds present in a molecule 
can be determined using their bond vibrations relative to the specific frequency of infrared 
radiation absorb by the molecule. The infrared radiation absorbed by the molecule is usually 
expressed in wavenumber (cm-1). Generally, infrared spectroscopy ranges from 400 – 4000 cm-1 
and can be used to identify specific functional group and chemical bonds present in a molecule. 
Infrared spectroscopy is very much similar to absorption and emission spectroscopy in that the 
frequency of infrared radiation absorb by a molecule correlates with the nature of the chemical 
bond present in that molecule. In this study, IR spectroscopy is used to confirm the existence of 
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certain functional group outshell of the CDs based NPs. The functional groups such as carbonyl, 


















CHAPTER 2. EXPERIMENTAL 
General Consideration 
UV-vis Spectroscopy 
The UV-vis analysis was done using a double beam UV-vis spectrometer (PharmaSpec 
UV-1700, PerkinElmer, USA). Various concentrations of the samples and intermediates were 
prepared in deionized water. The absorption spectra were taken in a one-centimeter path length 
quartz cuvette using deionized water as the reference material. Typically, the absorption readings 
were recorded from 800 nm to 190 nm. All the noticeable absorption maxima were noted and 
were reported.   
Fluorimeter 
The fluorescence emission spectra measurements were taken in an aqueous solution in air 
using a fluorimeter (FluoroMax-3, Jobin Yvon Inc, USA) with a slit width set at 10 nm for both 
excitation and emission monochromators using a Xenon arc lamp. Measurements were taken 
using a standard 1 cm quartz cuvette. For each sample, were recorded from 400 to 700 nm, the 
data was not corrected for instrument response. Also, since the samples exhibited an excitation-
dependent fluorescence as earlier mentioned, the emission spectra were taken at various 
excitation wavelengths.  
Infrared Spectroscopy  
The infrared spectra were recorded with a Shimadzu IRPrestige FTIR. Spectra of the neat 
powered were recorded using the ATR accessory. The infrared (IR) spectra was collected from 
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4000 cm-1 to 450 cm-1, and the quotation of wavenumbers (cm-1) to intensity abbreviations was 
strong (s), very strong (vs), and medium (m). Others include weak (w) and very weak (vw). 
Materials and Methods 
Ethylenediamine, citric acid, Doxorubicin hydrochloride (Dox•HCl), dialysis bag 
(MWCO = 1000 and 3500 Da), N-Hydroxysuccinimide (NHS), 3-(3-Dimethylaminopropyl)-1-
ethyl-carbodiimide (EDC), folic acid, gibco 1X phosphate buffered Saline pH 7.4 were all 
obtained from Fischer scientific, USA.  
Preparation of CDs, FA-CDs and FA-CDs-Dox 
Synthesis of CDs 
Two series of CDs were prepared as described by Zhu Shoujun and his co-workers with 
some modifications.63 The first series of CDs (Sample A) contained 2.000 g (10.41 mmol) of 
citric acid (CA) mixed with 63.74 µL (0.9540 mmol) of ethylenediamine (EN) (The 9:1 ratio), 
dissolved in 10.00 mL of deionized water. The second series of CDs (Sample B) contained 1.051 
g (5.470 mmol) of citric acid mixed with 335.0 µL (5.014 mmol) of ethylenediamine (1.1:1 
ratio), dissolved in 10.00 mL of deionized water. Both samples were transferred into an 
autoclave to react at 250 oC for 5 hours. The samples were collected and allowed to cool, after 
which they were dialyzed in the 3500 Da dialysis bag placed in 500 mL of deionized water for 6 
hours. The final samples were collected and lyophilized to obtain the brown-black product. 
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Synthesis of FA-CDs 
Two series of FA-CDs were prepared as the procedure described by Zhao et al.67  For the 
typical procedure, firstly, 20 mg of FA was sufficiently dissolved in 8 mL of 1X PBS buffer (pH 
7.4) to get a clear yellow solution. Then, 4 mL aqueous solution of 0.0260 g (0.1356 mmol) EDC 
and 0.0156 g (0.1355 mmol) NHS was added to the solution of FA. The mixture was treated by 
sonication at room temperature overnight to form the o-acrylisourea intermediate, then mixed 
with 2 mL of CDs (22 mgmL-1). The reaction was maintained under the same conditions for 
another 24 hours. Next, the solution was dialyzed (using MWCO 1 000 Da) against distilled 
water for one day to remove the excess FA or CDs. Lyophilization of the resulting product was 
then carried out to obtain a yellowish powder. 
Synthesis of FA-CDs-Dox 
Two series of FA-CDs-Dox were prepared as the procedure described by Yuan et al.8 For 
the typical procedure, 1 mL of FA-CDs solution (8 mg mL−1) and 1 mL of Dox solution (0.4 mg 
mL−1) were mixed with 2 mL of PBS at pH 7.4 under stirring to form a final solution system of 4 
mL. This solution was then allowed to stir for 24 hours on a sand bath set at 25oC and 200 rpm in 
the dark. After that, the resultant solution was dialyzed using a dialysis membrane (MWCO = 
3,500 Da) against 500 mL deionized water for 2 hours to remove any unreacted Dox or FA-CDs. 
The reaction was carried out in the dark to prevent photodegradation of Dox. A pink-reddish 




Spectral properties of all the NP, such as CDs, FA-CDs, and FA-CDs-Dox, were studied by 
UV-vis spectroscopy, fluorescence spectroscopy (FluoroMax-3, Jobin Yvon Inc, USA) using a 
standard quartz cuvette having a path length of 1 cm.  
The samples were also analyzed by Fourier-transform infrared spectroscopy (FTIR) by an IR 
Prestige-21 spectrometer (Shimadzu, USA) equipped with a Pike Miracle ATR sampling 
accessory. The spectra were obtained from the average of 16 scans from 600 to 4000 cm-1 at 4 
cm-1 resolution. 
Drug Load Content (DLC) and Drug Load Efficiency (DLE) 
 DLC and DLE were determined using the method as described by Kong et al.  with few 
modifications.88  The FA-CDs-Dox aqueous complex was dialyzed against pure water for 8 h 
and the concentration of unbound drug was measured spectrophotometrically at 485 nm and 
calculated using the standard calibration curve of Dox (linear line equation =2.27x +0.2229). The 
DLC and DLC were calculated using the following equations:  
𝐷𝐿𝐶(𝑚𝑔/𝑔) =
𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝐷𝑜𝑥 𝑙𝑜𝑎𝑑𝑒𝑑 𝑖𝑛 𝐹𝐴 − 𝐶𝐷𝑠
𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝐹𝐴 − 𝐶𝐷𝑠
 
  
            𝐷𝐿𝐸 (%) =
𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝐷𝑜𝑥 𝑙𝑜𝑎𝑑𝑒𝑑 𝑖𝑛 𝐹𝐴 − 𝐶𝐷𝑠
𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑡ℎ𝑒 𝐷𝑜𝑥
 𝑥 100% 
In-vitro Drug Release 
The pH dependent release of Dox from FA-CDs-Dox complex was also investigated. For a 
typical procedure, 3 mL of FA-CDs-Dox aqueous solution was sealed in a dialysis bag (MWCO 
= 1,000 Da) and in 120 mL PBS solution at pH 5.0 and heated at 37 oC under mild intermittent 
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stirring. The samples were collected at intervals of 30 min for 3 h and then at intervals of 24 h 
for 3 days. At regular intervals, 2 mL of the release medium in PBS was taken and replaced with 
fresh PBS solution of the same volume. The standard calibration curve was taken at 485 nm and 
the amount of released Dox was determined. Determination of the concentration of drug released 
in the mixture was done using the formula y = mx+b, y is absorbance of the unknown, m is 
slope, b is intercept, x is concentration (mg/mL)89. Slope = 22.000, intercept = -0.0467, R2 = 






CHAPTER 3. RESULTS AND DISCUSSION 
Synthesis of CDs 
The synthesis of CDs was done using one pot hydrothermal treatment of citric acid and 
ethylenediamine.63 Scheme 1 below shows the reaction scheme. The surface of prepared CDs 
contains the primary amine and carboxylic acid functional groups which are facile for further 
modification. The same technique was applied for synthesis of both sample A and B from 
different ratio of starting materials. A low yield of approximately 33% Wt. was obtained for 
sample A and a yield of 35% wt. was obtained for sample B. The reason for low yields of this 
step may because some of the products might have been washed off during the dialysis 
procedure.   
It was noted that the lyophilization process of sample B took approximately 48 hours which 
is relatively shorter compared to sample A, which took over 120 hours. This result also shows 
that the changing the ratio of citric acid and ethylenediamine can influence the purification 




Scheme 1. Hydrothermal synthesis of CDs. (The ratio of functional groups, or starting material is 




UV-vis and FL Spectroscopy Result of CDs (Sample A and B) 
UV-vis Results (Sample A)  
The UV-vis of CDs Sample A (Fig. 13) reveals that the CDs solution (0.1 mg mL-1) showed 
characteristic absorption peak at 201 nm and 346 nm. Those peaks indicate the presence n-π* 
and π-π* transitions of the carbonyl group on the surface of the CDs.83 The results are similar to 
the data reported from Dr. Shoujun Zhu and his group, in which an aqueous solution of CDs 
showed a major absorption peak at 344 nm.63   
 
Figure 13. UV-vis of 0.1 mgmL-1 aqueous solution of CDs (Sample A) 
UV-vis (Sample B)  
The UV-vis analysis of CDs sample B (Figure 14) was carried out the same way as 
























peak at 206 nm and 337 nm. The absorption at 337 nm of sample B is much higher than sample 
A for all concentrations, this may be due to the hyperchromic effect of the N-H functional group 
close to the carbonyl group. The absorption peaks at 206 nm and 337 nm also reveals the 
presence of π-π* and n-π* transitions of the carbonyl group on the surface of the CDs. Like 
sample A, solution of sample B also showed blue luminescence when viewed with a hand-held 
UV lamp as shown in Figure 15.  
 
 



















Figure 15. CDs solution (0.1 mg mL-1) of sample B (left) and water (right) when view under a 4-
Watt, 254/365 nm UVGL-15 Compact UV lamp. 
 
The Fluorescence (FL) Spectroscopy Results 
The fluorescence analysis of CDs was also done using 0.1 mg mL-1 aqueous solution of 
the sample. It was observed that CDs exhibited an excitation dependent fluorescence. The CDs 
solution (0.1 mg mL-1 ) from sample A was excited at different wavelengths from 320 nm – 380 
nm (Fig. 16). The emission maximum was at 450 nm at an excitation wavelength of 360 nm. The 
emission at 360 nm appears to be highest, while emission at excitation 320 nm showed the 
lowest intensity.  The FL result explains why aqueous solution of CDs shows a blue 





Figure 16. Fluorescence spectra of CDs (Sample A) at different excitation wavelength (320 nm 
– 380 nm). 
The fluorescence analysis of CDs sample B was also investigated at wavelengths 
excitation of 320 nm – 380 nm (Fig. 17). For sample B, the maximum emission was also at 450 
nm at an excitation wavelength of 360 nm. The emission at 360 nm appears to be highest, while 
emission at excitation 320 nm showed the lowest intensity. This result is very much similar to 
sample A CDs. The only noticeable difference is the intensity of the peaks. The emission 

























Figure 17. FL spectra of CDs (Sample B) at different excitation wavelength (320 nm – 380 nm). 
The UV and FL results of the CDs samples showed that changing the ratio of the starting 
materials could have a slight impact on the  optical properties of CDs – the intensity of the FL 
spectra are higher in sample B than in sample A as shown in Figure 16 and 15 respectively.  
FTIR Results  
The FTIR analysis was carried out for determination of the possible functional groups 
present. Few milligrams of the pure solid sample were taken for the analysis. As shown in Figure 
18 below, the FTIR spectrum shows a very strong peak at 1693 cm-1 which reveals the presence 
of a carbonyl carbon (C=O). The presence of a C-H stretching is also confirmed with a peak at 
2939 cm-1. The broad absorption peak from 3000 – 3483 cm-1 indicates the presence of O-H/N-H 
functional group on the surface of the CDs. In the fingerprint region, the peak at 1404 cm-1 



























The very strong peak at 1693 cm-1 corresponds to the C=O stretch of carboxylic acid, 
which could be explained due to the high ratio of citric acid to ethylenediamine used in the 
synthesis of sample A.  
   
 
Figure 18. FTIR spectrum of CDs (Sample A). 
 
On the other hand, the FTIR spectrum of CDs from sample B (Figure 19) shows the C=O 
absorption peak at 1651 cm-1. Compared to sample A, the C=O stretch of sample B is less strong 
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or broad. The very strong peak at 1539 cm-1 represents N-H deformation and C-N stretching 
vibration of amide.67 The spectra of sample B shows stronger and broad N-H stretching peak 
compared to sample A. This could be because the precursor was used in the same ratio of starting 
materials which allow for more primary amine or amide groups in sample B.   The broad 
absorption peak at 3228 cm-1 represents N-H/O-H group in primary amine and carboxylic acid, 
while the peaks at 1435 cm-1 represent the C-H asymmetric stretch.   
 
Figure 19. FTIR spectrum of CDs (Sample B). 
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The FTIR spectra obtained for CDs were compared to citric acid which was the dominant 
precursor in the starting material used. First, the absorption peak of C=O for citric acid is at 1743 
and 1697 cm-1 while the C=O peak for sample A and B are at 1693 cm-1  and 1651 cm-1 
respectively. Additionally, the O-H functional group of citric acid as shown in Figure 20 is sharp 
and medium with an absorption peak at 3286 and 3495 cm-1.The peaks are comparably broad and 
medium for –OH group in the CDs samples. Even though both CDs samples showed the 
presence of N-H/O-H bonds, the peak intensity and shape are different compared to citric acid.  
Nonetheless, the C-O absorption peaks in the fingerprint region at 1215 cm-1 are similar in all 
three spectra. Shoujun Zhu and his group showed similar IR spectra for CDs prepared using the 
hydrothermal treatment from citric acid and ethylenediamine.63  The IR spectra show that sample 
A is more similar to citric acid particularly at the C=O absorption band, this may be because it 





Figure 20. FTIR spectra of citric acid 
 
Synthesis of FA-CDs 
Synthesis of the FA-CDs complex was completed using EDC/NHS coupling reaction 
(carbodiimide crosslinker).  The amine group on the surface of the CDs was conjugated with the 
carboxylic acid group in folic acid.67 This method allows for the creation of a non-cleaveable 
covalent bond between CDs and FA. The reaction was carried in two steps as shown in Scheme 2 




Scheme 2. Activation of the carboxylic acid functional group using EDC and NHS.91 
 
Scheme 3. Formation of a non-cleavable linker between CDs and FA. (The drawings in the 
scheme are not according to the actual scale and ratio. For clarification, only one carboxylic acid 
and one amine group are shown for CDs; only one FA is shown to react with CDs, and only a 
few of Dox attach to FA-CDs).91 
The first step of the reaction typically involves activation of the acid functional group of 
folic acid using EDC and NHS. This allows for the easy conjugation of the amine functional 
group of CDs. The reaction was carried out in a PBS buffer solution the whole time to ensure 
that the reactants remain stable . The resulting solution from the experiment was subjected to 
dialysis to remove unreacted reagents and for purification of the sample. The desired solid 
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products FA-CDs were obtained after purification using dialysis and lyophilization. The drying 
process of FA-CDs of both samples took relatively the same time around 48 hours. And powder 
yellow solid products were obtained with decent yields approximately 40% wt. The desired 
product were stored for further characterization. 
UV-vis and FL spectroscopy result of FA-CDs (from CDs Sample A and B) 
UV-vis Analysis of FA-CDs (from CDs sample A) 
The FA-CDs complex showed three characteristics absorption at 201 nm, 279 nm, and 
342 nm. The absorption peak at 201 nm and 342 nm are evidence of the presence of CDs, while 
the peak at 279 nm is characteristic of FA as reported by existing literature.67,69 This results 
represents the likely conjugation of CDs to FA. The UV-vis absorption spectrum was compared 
to spectrum of pure FA solution, using the same concentration (0.1 mg mL-1) as shown in Figure 
21. The FA-CDs from CDs sample A have characteristic absorption peaks of FA at 290 and 342 
nm. and the characteristic absorption peak of CDs sample A at 344 nm. Those data indicate the 
successful functionalization of FA onto CDs surface. The absorption peaks of FA-CDs at 342 nm 
are enhanced since both free FA and CDs have characteristic absorption peak in this region. 
Also, it was noted that the absorbance readings at the higher end of the spectrum from 300 nm – 





Figure 21. UV-vis of obtained FA and FA-CDs (from CDs Sample A).  
UV-vis Analysis of FA-CDs (from CDs Sample B) 
The absorbance results elucidated that the product FA-CDs contains both CDs and FA. 
Detailed analysis of the absorbance spectra (Figure 22) showed that the spectra of pure FA, pure 
CDs from sample B, and FA-CDs are comparable. In addition to the unique absorbance of FA at 
283 nm,67 the FA-CDs showed the absorbance peaks at 201 nm and 340 nm corresponding to 
CDs. The UV-vis spectra data for both FA-CDs are similar, but the intensities are different. The 
FA-CDs from sample A showed characteristic absorbance spectra at 201 nm, 282 nm and 342 




















Figure 22. UV-vis spectra of obtained FA & FA-CDs (from CDs Sample B). 
FL Spectroscopy of FA-CDs (from CDs Sample A) 
The FL spectra of FA and FA-CDs were done as shown in Figures 23 and 24 to obtain the 
emission wavelength of the two samples. The maximum emission was at the excitation wavelength 
of 360 nm and the maximum emission peaks are at 440 nm and 450 nm for FA and FA-CDs 
respectively. Additionally, it was noted that the emission intensity of FA-CDs is enhanced 


























Figure 23. FL spectra of pure FA (0.1 mg mL-1) at different excitation wavelength (320 nm – 
380 nm). 
 
Figure 24. FL spectra of FA-CDs 0.1 mg mL-1 (from CDs Sample A) at different excitation 





























































FL Spectroscopy of FA-CDs (from CDs Sample B) 
The FL intensity of FA-CDs (prepared from CDs sample B) is somewhat similar to the 
FA-CDs prepared from sample A. Both FA-CDs samples exhibited an excitation-dependent 
wavelength property by having the maximum emission peak at 450 nm at an excitation 
wavelength of 340 and 360 nm respectively as shown in Figure 24 and 25, the λmax here appears 
to shift at different excitation. The major difference is the emission peak intensity of the FA-CDs 
from sample B which is much higher than FA-CDs from sample A at all excitation wavelengths.  
 
Figure 25. FL spectra of FA-CDs 0.1 mg mL-1 (from CDs Sample B) at different excitation 

































FTIR Results of FA 
Figure 26 below shows FTIR spectroscopy of pure FA.  The spectrum has the 
characteristics absorption peaks at 1639 cm-1 corresponding to C=O of amide (-CONH2), and at 
1693 cm-1 corresponding to C=O of carboxylic acid (-COOH). The peaks at 1604, 1485, 1519 
cm-1 correspond to phenyl and pterin rings.67 The peak at 2927 cm-1 corresponds to C-H 
stretching, and the peaks at 3097, 3545 cm-1 matches that of O-H of carboxylic acid and N-H 
stretching of primary amine.  
 
 
Figure 26. FTIR spectra of pure FA. 
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FTIR Results of FA-CDs (from CDs sample A) 
Both FA-CDs samples show the characteristic peaks present in its precursor – CDs and 
FA. In the FA-CDs (from sample A CDs) IR spectrum, there are noticeably peaks at two 
different amides absorption band (I and II) at 1689 cm-1 (C=O) and 1639 cm-1 (N-H bending) 
The peaks at 1604, 1481, 1516 cm-1 corresponds to phenyl and pterin rings. The presence of C-H 
stretching frequency at 2839 and 2927 cm-1 was also observed, the band observed at 1180 cm-1 
which is absent in the spectra of pure FA, corresponds to C-O-C stretching.67  The peaks from 
2839 – 3541 cm-1 appears more broad in the spectra of FA-CDs compared to pure FA.  
 
Figure 27. FTIR spectra of FA-CDs (from CDs sample A). 
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FTIR Results of FA-CDs (from CDs sample B) 
For the FTIR spectrum of FA-CDs (prepared from CDs sample B), the absorption peaks 
at 1604 cm-1, and 1485 cm-1 representing the presence of C=C can be seen in the FA spectrum. 
The C=O band and the N-H bending peak appear at 1685 cm-1, 1639 cm-1 respectively, which are 
similar to the FA-CDs from sample A. From the comparison data of FA and FA-CDs, it confirms 
that the attempt to conjugate CDs to FA was successful.92,93  
 
Figure 28. FTIR spectra of FA-CDs (from CDs sample B). 
60 
 
Synthesis of FA-CDs-Dox 
The synthesis of the FA-CDs-Dox NPs was achieved due to Dox ability to exist as a 
cation in aqueous solution of pH 7.4, at which the amino group is protonated.80  Thus, Dox can 
be potentially loaded on the negatively charged NPs via electrostatic interaction and π-π 
stacking.14,30,81 Scheme 4 below shows the reaction scheme between FA-CDs and Dox. Since 
Dox has a unique UV-vis absorbance peak, it is possible to confirm the successful formation of 
the FA-CDs-Dox complex using spectroscopic techniques.  
 
 
Scheme 4. Electrostatic interaction of FA-CDs and Dox. The drawings in the scheme are not 
according to the actual scale and ratio. For clarification, only one carboxylic acid and one amine 
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group are shown for CDs; only one FA is shown to react with CDs, and only a few of Dox attach 
to FA-CDs.91 
 
UV-vis Analysis Result of FA-CDs-Dox (prepared from CDs Sample A) 
Dox has a unique absorbance peak at 480 – 485 nm,11,88,94 the similar peak at 480 nm is 
quenched in our prepared FA-CDs-Dox. The solution of  FA-CDs-Dox (prepared from CDs 
sample A) also  has the absorbance peaks characteristic of FA-CDs, at 281 nm and 344 nm.  
 






















UV-vis Analysis Result of FA-CDs-Dox (from CDs Sample B) 
 Similar results were observed in FA-CDs-Dox from sample B with slightly differences. 
There is an absorbance peak at 480 nm in FA-CDs-Dox characteristic of Dox.  It is noticeable 
that the absorbance at this wavelength is quenched in FA-CDs-Dox compared to Dox for both 
FA-CDs-Dox samples. The solution of FA-CDs-Dox also shows the characteristic absorbance 
peaks of FA-CDs, at 290 nm and 340 nm, but with lower intensity compared to the other series. 
 
Figure 30. UV-vis spectra of pure Dox and FA-CDs-Dox (from sample B). 
 
FL Spectroscopy of FA-CDs-Dox  
It was observed that the maximum emission of FA-CDs-Dox (from CDs sample A) was 




















intensity. The maximum emission of FA-CDs-Dox (from CDs sample B) was at 440 nm at an 
excitation of 340 nm. It was noticed that once the maximum emission is reached at an excitation 
of 340 nm, the emission intensity decreases for every 10 nm increase in the excitation 
wavelength. 
 
Figure 31. FL spectra of FA-CDs-Dox 0.1 mg mL-1 (from CDs sample A) at different excitation 
wavelength (320 nm – 380 nm). 
 
Both FA-CDs-Dox exhibits an emission  λmax at 440 nm at excitation wavelength of 340 
and 360 nm respectively. However, the emission intensity is obviously higher for FA-CDs-Dox 
(from CDs sample B) than for FA-CDs-Dox (from CDs sample A). Figures 31 and 32 shows the 


































Figure 32. FL spectra of FA-CDs-Dox 0.1 mg mL-1 (from CDs sample B) at different excitation 
wavelength (320 nm – 380 nm). 
 
FTIR Results of FA-CDs-Dox (from CDs sample A) 
As shown in figure 31 below, the FTIR spectrum of pure Dox shows characteristic 
absorption peak at 1728 cm-1 corresponding to C=O stretching vibrations. The peaks at 1234, 1616, 
2897, 3317, 3522 cm-1 match C-O stretching, C=C stretching, C-H stretching, N-H stretching, and 
O-H stretching molecular vibrations respectively. For the new prepared FA-CDs-Dox from sample 
A (Figure 34), there are the  absorption bands at 3105 - 3564 cm−1 corresponded to O-H and N-H 
stretching vibrations; the typical absorption band of C=O stretching vibrations can be observed 
around 1604 – 1685 cm−1; the peak at 1296 cm−1 is characteristic of C-N stretching vibrations; and 

































Figure 34. FTIR spectra of  FA-CDs-Dox (from CDs sample A) 
 
FTIR Results of FA-CDs-Dox (from CDs sample B) 
 The IR spectrum below (Figure 35) shows absorption peaks that indicates the evidence of 
conjugation of FA-CDs and Dox via electrostatic interaction. The broad peak at 3093  – 3321 
cm–1  reveals the presence of O-H stretching vibration, and absorption peak at 2978 cm-1 
represents the presence of C-H stretching vibrations. The peaks at 1689 cm-1  and 1651 cm-1 
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corresponds to C=O and N-H of amide, while absorption peaks at 1539 cm-1  and 1134 cm-1  
corresponds to N-H bending and C-O stretching molecular bonds respectively. Both samples 
showed absorption band at 3564 – 3093 cm-1 the amide peak band at 1689 – 1685 cm-1 for C=O 
and 1651 – 1654 cm-1 for N-H, peak at 1604 cm-1 and 1400 cm-1  appeared in both samples 
corresponding to C=C. 
 
 
Figure 35. FTIR spectra of  FA-CDs-Dox (from CDs sample B). 
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Determination of Concentration 
 The concentration of each component present in FA-CDs-Dox was determined using 
standard calibration curve. Standard solutions of different concentrations were prepared for FA-
CDs and FA-CDs-Dox from FA and Dox. The UV absorbance values for each of the concentration 
was recorded at specific signature wavelength peculiar to each nanoparticle. After which, a 
calibration curve was set and the unknown concentration of each component of the final mixture 
of FA-CDs-Dox was determined using the known values of the absorbance and concentration of 
the standards. 
Calibration Curve 
Different concentration of Dox was prepared 0.075 mg mL-1, 0.050 mg mL-1, 0.025 mg 
mL-1, 0.010 mg mL-1, 0.005 mg mL-1, 0.0010 mg mL-1, and blank as shown in Table 3. The 
absorbance of the samples at 485 nm were taken and a standard calibration curve as shown in 
Figure 36 below was obtained. 
Table 3. Different concentration of Dox and Absorbance Measured 











Figure 36. Calibration curve of Dox showing concentration (in mg/mL) against absorbance. 
Calculation of Concentration of FA in FA-CDs (from CDs sample B) 
The concentration of FA in FA-CDs was determined by using similar method described 
above, this involves measurement of absorbance of different known concentration of FA at the 
absorbance of 280 nm as shown in Table 4. 
Table 4.  Absorbance of Various Concentration of FA at 280 nm  
Weight of FA used (mg) Concentration (mg mL-1) Absorbance (280 nm) 
1 0.0001 0.1259 
2 0.002 0.1592 
5 0.005 0.2193 
10 0.01 0.3333 
























A graph of absorbance against concentration was plotted, using the formula y = mx + b,  where y 
= absorbance of unknown substance, m = slope of graph of known concentration, x = 
concentration of unknown substance, b = intercept along y axis.  
 
 
Figure 37. Calibration curve showing UV absorption of various concentration of FA. 
 
Estimation of FA Concentration in FA-CDs  
Using the formula above, the slope (m) of the graph is calculated to be 21.549, while the 
intercept (b) on the y axis is 0.1181. Absorbance of the unknown sample (FA-CDs), 0.1 mg mL-1 
(1mg/10mL) of FA-CDs solution was prepared, absorbance was measured at 280 nm to be 0.876, 
which is the fingerprint absorbance of FA.  
Substituting into the formula y = mx + b and solving for x; 
y = 0.8760 (absorbance of unknown compound);  
b = 0.1181 (intercept);  






















m = 21.549 (slope) 
x (concentration of the unknown) = 0.03511 mg mL-1   
FA used for preparation: 20 mg/(8+4+2)mL= 1.42 mg/mL 
FA in FA-CDs: (1.42 mg/mL x 1 mL - 0.03511 mg/mL x1 mL)/1 mL= 1.3849 mg/mL 
Estimation of In Vitro Drug Release 
To investigate the release properties and load efficiency of FA-CDs-Dox, 3 mL of the 
resultant solution was dialyzed using a dialysis membrane (MWCO = 1,000 Da) against 120 mL 
PBS buffer solution at pH 7.4 for 72 hours. In some intervals, 1 mL of the release medium was 
taken and replaced with equal volume of PBS. A UV-vis spectroscopy of the sample was then 
taken at an absorbance of 485 nm, the concentration of the sample is then calculated using the 
standard calibration curve to determine the sample’s concentration and amount of drug 
released.88  
At different intervals of 1 hrs, 6 hrs, 18 hrs, 47 hrs, 51 hrs, 67 hrs and 72 hrs, 1 mL of the 
release medium was taken, and replaced with equal volume of the buffer solution and the 
absorbance measured, Table 5 below shows the result of the data obtained. The amount of drug 
in the released medium was determined using excel with the formula; 
Amount of drug = Concentration (mg/mL) × Volume of medium (mL) × dilution factor. 






Table 5.  Showing Concentration of Different Samples and the Cumulative Drug Release (CDR) 






Amt. (mg) CDR (%) 
1 1 0.008 0.00249 0.298 29.824 
2 6 0.018 0.00294 0.353 35.278 
3 18 0.036 0.00376 0.451 45.096 
4 47 0.055 0.00462 0.555 55.459 
5 51 0.061 0.00489 0.587 58.732 
6 67 0.068 0.00521 0.626 62.550 
7 72 0.077 0.00562 0.675 67.459 
 
 
























Determination of Dox Concentration in FA-CDs-Dox (from CDs sample B) 
1 mL of FA-CDs solution (8 mg mL−1) and 1 mL of Dox solution (1 mg mL−1) were mixed 
with PBS at pH 7.4 under stirring to form a final solution system of 4 mL. This solution was then 
allowed to react for 48 hours at constant stirring on a sand bath set at 25 ⁰C and 200 rpm in the 
dark to prevent photodegradation of Dox.  
To investigate the release properties and load efficiency of FA-CDs-Dox, 3 mL of the 
resultant solution was dialyzed using a dialysis membrane (MWCO = 1,000 Da) against 120 mL 
PBS buffer solution at pH 7.4 for 72 hours. In some intervals, 1mL of the release medium was 
taken and replaced with equal volume of PBS. A UV-vis spectroscopy of the sample was then 
taken at an absorbance of 485 nm, the concentration of the sample is then calculated using the 
standard calibration curve to determine the sample’s concentration and amount of drug released.  
Calculation of Weight of the Unknown (Wf) 
Since concentration (mg mL -1) = mass/volume (mL) 
Volume of FA-CDs-Dox after dialysis was 2.5 mL 
 0.0967 mg mL-1 = mass/ 2.5 mL  
Mass (Wf) = 0.24175 mg  
DLC and DLE Calculation (Sample B) 












DLC = 9.48 %; DLE = 75.8 % 
 
Table 6. Drug Load Characteristics of FA-CDs-Dox (sample B) 
Sample Weight of FA-
CDs (mg) 






FA-CDs-Dox 8.0 1.0 9.48 75.8 
 
Discussion on DLC and DLE 
Using the technique described above, FA-CDs-Dox from sample B showed more drug 
load content (9.48%) compared to sample A (4.45%), this may be because 1.0 mg of Dox was 
loaded to the FA-CDs NP (prepared from sample B), while 0.4 mg of Dox was loaded on FA-
CDs (prepared from sample A). Even though the amount of Dox used is higher in sample B than 
in sample A, the load efficiency is higher in sample A (89.1%) than in sample B (75.8%). 
Unsurprisingly, by increasing the weight of Dox used, it is possible to increase the drug load 
content of the samples but not necessarily the efficiency. Generally, both samples showed good 
load content and efficiency. This result also proves that it is possible to load Dox on the FA-CDs 




CHAPTER 4. CONCLUSION AND FUTURE WORK 
 
Two series of CDs, FA-CDs and FA-CDs-Dox, were successfully prepared in the lab and 
their physical properties was observed and compared. The optical properties of the all samples 
were examined using UV-vis, FL spectroscopy, and FTIR. The FA-CDs-Dox showed high load 
capacity, efficiency and drug release.  It was also observed that changing the ratio of the 
precursor of CDs have little effect on the overall optical properties, the pharmaceutical test on 
the diagnostic and therapeutic anticancer potential of the NPs are still under investigation. 
However, CDs prepared from equal ratio of citric acid and ethylenediamine might be preferable 
to due ease of preparation, and better optical properties. The results showed that CDs based drug 
delivery vehicles can have effective application in cancer chemotherapy.  Future studies will 
attempt to focus on changing the chemotherapeutic agent. The NP will be tested on different 
cancer cell lines to monitor its efficiency as well as effectiveness and if it is selective to cancer 
cell tumors. The in vivo studies of the NPs will also be examined as well as future clinical 
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